Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Topiramate is indicated as a treatment of epilepsy and migraine
These observations are procedural in nature and none of them are related to data integrity
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Delivers robust earnings performance, successfully navigating a dynamic environment
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Subscribe To Our Newsletter & Stay Updated